DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03824002

CompletedPhase 4

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Arterial Stiffness and Endothelial Function Indexes, Relationships With Clinical and Laboratory Variables in a Group of Diabetic Patients in Treatment With Dulaglutide: a Case-control Study

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

92

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Change from Baseline Reactive Hyperemia Index at 3 and 9 months

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03824002
Org study ID21772

Timeline

Milestones

Study start2017-04-01actual
Primary completion2017-10-01actual
Study completion2018-04-20actual
Study first posted2019-01-31actual
Last update posted2019-01-31actual

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age90 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•diabetes mellitus

Exclusion criteria

•cancer, severe ckd, end stage liver disease

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
5
Weight & body composition
1
Glycemic / diabetes
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change from Baseline Body Mass Index at 3 and 9 months

Time frame:0 months, 3 months and 9 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change from Baseline glucose at 3 and 9 months

Time frame:0 months, 3 months and 9 months

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Cardiometabolic biomarkers

5 endpoints
Secondary/protocol endpoint

Change from Baseline systolic blood pressure at 3 and 9 months

Time frame:0 months, 3 months and 9 months

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change from Baseline cholesterol at 3 and 9 months

Time frame:0 months, 3 months and 9 months

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change from Baseline triglycerides at 3 and 9 months

Time frame:0 months, 3 months and 9 months

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change from Baseline diastolic blood pressure at 3 and 9 months

Time frame:0 months, 3 months and 9 months

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change from Baseline Pulse Wave Velocity at 3 and 9 months

Time frame:0 months, 3 months and 9 months

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Change from Baseline Reactive Hyperemia Index at 3 and 9 months

Time frame:0 months, 3 months and 9 months

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.